Cyclophosphamide for the treatment of systemic lupus erythematosus

Lupus

Volumn 10, Issue 3, 2001, Pages 154-161

  Takada, K ^a   Illei, G G ^a   Boumpas, D T ^a,b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Combination therapy; Cyclophosphamide; Flare; Remission; Systemic lupus erythematosus

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; NUCLEOSIDE ANALOG;

AMENORRHEA; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0035051116     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301671376017     Document Type: Review

References (103)

1. Nitrogen mustard in treatment of systemic lupus erythematosus
2. Immunosuppressive drug therapy of systemic lupus erythematosus
3. Antineoplastlc agents
4. Immunosuppression by alkylating agents - Tolerance induction
5. Suppression of human B lymphocyte function by cyclophosphamide
6. The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: Inhibition of helper T-cell induction in vitro
7. 1hybrid mice
8. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy
9. Studies of cyclophosphamide therapy in murine lupus - Effect of combining multiple subsets into a single randomized study
10. Systemic lupus erythematosus - Immunoregulatory therapies
11. Cytotoxic drugs in treatment of non-malignant diseases
12. Treatment of lupus nephritis with cyclophosphamide
13. Cyclophosphamide in treatment of systemic lupus erythematosus: 7 y experience
14. Cyclophosphamide in systemic lupus erythematosus
15. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine
16. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis
17. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
18. Cyclophosphamide or azathioprine in lupus glomerulonephritis: A controlled trial: Results at 28 months
19. Cyclophosphamide treatment for systemic lupus erythematosus
20. Leukemia after cytotoxic chemotherapy - A pyrrhic victory?
21. Cyclophosphamide and malignancy
22. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis
23. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
24. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
25. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis
26. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis
27. Intermittent intravenous treatment of lupus nephritis with cyclophosphamide: A four-year experience with twenty-four patients
28. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide
29. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network
30. Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis
31. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
32. Intermittent intravenous cyclophosphamide therapy for lupus nephritis
33. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus
34. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis
35. Intravenous cyclophosphamide pulse therapy on children with severe active lupus nephritis
36. Lupus nephritis in children: A longitudinal study of prognostic factors and therapy
37. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide
38. A controlled trial of plasmapheresis therapy in severe lupus nephritis
39. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Preliminary results of the LPSG-trial
40. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis
41. Severe infections in plasmapheresis-treated systemic lupus erythematosus
42. Renal flares in patients with proliferative lupus nephritis (LN) treated with immunosuppressive therapy: Classification, prevalence and outcomes
43. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal
44. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis
45. The favorable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus
46. Pulmonary hemorrhage in systemic lupus erythematosus
47. Diffuse alveolar hemorrhage and systemic lupus erythematosus: Clinical presentation, histology, survival, and outcome
48. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases
49. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus
50. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus
51. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus
52. Pulse cyclophosphamide for severe neuropsychiatric lupus
53. Outcome criteria for lupus nephritis trials: A critical overview
54. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: An open trial
55. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus
56. Systemic lupus erythematosus associated with transverse myelitis and parkinsonian symptoms
57. Acute transverse myelitis in systemic lupus erythematosus: A case of rapid diagnosis and complete recovery
58. Acute transverse myelitis in systemic lupus erythematosus: Magnetic resonance imaging and review of the literature
59. Transverse myelopathy in SLE: Clinical features and functional outcomes
60. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis patients
61. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
62. Preserving ovarian function in patients receiving cyclophosphamide
63. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus
64. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis
65. Effects of immunosuppressive drugs during pregnancy
66. The relationship of gonadal activity and chemotherapy-induced gonadal damage
67. Prevention of gonadal damage during cytotoxic therapy
68. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study
69. Gonadotropin-releasing hormone agonists and the skeleton
70. Leuprolide acetate and bone mineral density measured by quantitive radiography
71. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism
72. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: Changes in vertebral bone mass and serum estradiol and calcitonin
73. Goserelin (Zoladex) and the skeleton
74. Use of testosterone to prevent cyclophosphamide-induced azoospermia
75. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - Comparative study on the uroprotective efficacy of thiols and other sulfur compounds
76. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - Experimental studies on the urotoxicity of alkylating compounds
77. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - Profile of action of sodium 2-mercaptoethane sulfonate (mesna)
78. Urinary complications of cyclophosphamide therapy: Etiology, prevention, and management
79. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosus
80. The history of the oxazaphosphorine cytostatics
81. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cyctitis in marrow transplantation: A prospective randomised study
82. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation
83. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: A randomized trial
84. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study
85. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up
86. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis
87. Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus
88. Mycophenolate mofetil therapy in lupus nephritis: Clinical observation
89. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation
90. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation
91. Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation
92. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation
93. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity
94. 4-Hydroperoxycylohposphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells
95. Nucleoside analogs: Cellular pharmacology, mechanisms of action and strategies for combination therapy
96. Fludarabine (FAMP) and cyclophosphamide therapy in chronic lymphocytic leukemia (CLL)
97. Reversal of advanced murine lupus nephritis with combined CTLA 4Ig and cyclophosphamide
98. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: A preliminary study
99. Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide
100. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
101. Treatment of lupus nephritis - A work in progress